{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-013204","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.640881+00:00","generated_at":"2026-05-26T22:22:18.226261+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop","bullets":["Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).","Cash $3.5M at Dec 31, 2024; raised $2.9M in Jan 2025; expects funding through Q2 2025.","INM-901 Alzheimer's preclinical data reduced neuroinflammatory markers; INM-089 IVT formulation for dry AMD.","Director Janet Grove resigned after withheld votes at Dec 2024 AGM; board to find replacement.","BayMedica net income $0.23M (+189%) despite revenue drop due to cost cuts."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-013204","json":"https://secwatch.observer/filing/0001213900-25-013204.json","markdown":"https://secwatch.observer/filing/0001213900-25-013204.md","text":"https://secwatch.observer/filing/0001213900-25-013204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/0001213900-25-013204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/ea0230951-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:22:18.226261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}